Literature DB >> 19505378

Pidotimod: a reappraisal.

P Riboldi, M Gerosa, P L Meroni.   

Abstract

Pidotimod (Polimod ) is a synthetic dipeptide molecule with biological and immunological activity on both the adaptive and the innate immune responses. In vitro studies, both from animal and human specimens, have documented a good activity on innate and adaptive immune responses and have been confirmed by in vivo studies. These activities have been applied in clinical studies demonstrating the efficacy of pidotimod in reducing the rate of recurrent infections of the upper respiratory and urinary tracts in children. The same results were obtained in recurrent respiratory tract infections in adults. Interestingly, these effects are more evident in the setting of immune defects such as senescence, Downs syndrome, and cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505378     DOI: 10.1177/039463200902200201

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  10 in total

1.  The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod(PTD).

Authors:  Xiaofang Hu; Wei Zhang; Lu Wang; Nan Wan; Bing Wang; Weiwei Li; Hui Hua; Xu Hu; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-08-06       Impact factor: 3.452

2.  Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs).

Authors:  Yiming Meng; Qiushi Wang; Zhenjie Zhang; Enhua Wang; Nicollas P Plotnikoff; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

3.  Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.

Authors:  Ying Zhao; Bo Huang; Shiguang Huang; Huanqin Zheng; Yun-quan Li; Zhao-rong Lun; Jilong Shen; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-06-20       Impact factor: 2.289

4.  Complementary treatment with oral pidotimod plus vitamin C after laser vaporization for female genital warts: a prospective study.

Authors:  S Zervoudis; G Iatrakis; P Peitsidis; A Peitsidou; L Papandonopolos; M K Nikolopoulou; L Papadopoulos; R Vladareanu
Journal:  J Med Life       Date:  2010 Jul-Sep

5.  Pidotimod: the past and the present.

Authors:  Gian Vincenzo Zuccotti; Chiara Mameli
Journal:  Ital J Pediatr       Date:  2013-12-06       Impact factor: 2.638

6.  The Immune-Modulator Pidotimod Affects the Metabolic Profile of Exhaled Breath Condensate in Bronchiectatic Patients: A Metabolomics Pilot Study.

Authors:  Maria D'Amato; Debora Paris; Antonio Molino; Paola Cuomo; Andrea Fulgione; Nunzia Sorrentino; Letizia Palomba; Mauro Maniscalco; Andrea Motta
Journal:  Front Pharmacol       Date:  2019-10-03       Impact factor: 5.810

Review 7.  Immunostimulants in respiratory diseases: focus on Pidotimod.

Authors:  Francesca Puggioni; Magna Alves-Correia; Manar-Farouk Mohamed; Niccolò Stomeo; Riccardo Mager; Massimiliano Marinoni; Francesca Racca; Giovanni Paoletti; Gilda Varricchi; Veronica Giorgis; Giovanni Melioli; Giorgio Walter Canonica; Enrico Heffler
Journal:  Multidiscip Respir Med       Date:  2019-11-04

Review 8.  Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.

Authors:  Jialing Yin; Chengcheng Li; Chunhong Ye; Zhihui Ruan; Yicong Liang; Yongkui Li; Jianguo Wu; Zhen Luo
Journal:  Comput Struct Biotechnol J       Date:  2022-01-31       Impact factor: 7.271

9.  Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression.

Authors:  Sonia Carta; Michela Silvestri; Giovanni A Rossi
Journal:  Ital J Pediatr       Date:  2013-05-10       Impact factor: 2.638

10.  The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3).

Authors:  Francesca Caccuri; Antonella Bugatti; Silvia Corbellini; Sara Roversi; Alberto Zani; Pietro Mazzuca; Stefania Marsico; Arnaldo Caruso; Cinzia Giagulli
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.